Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2018

View Archived Issues

AD brains have splicing problem

Protecting cartilage in arthritis

Insm1 keeps hair cells in 'n' out

Amgen begins first-in-human study of AMG-427 in relapsed or refractory AML

Modest improvements to visual acuity observed following retinal gene therapy for choroideremia

TLR9-targeted oligonucleotide NF-KappaB inhibitor developed for B-cell lymphoma

Evobrutinib shows reduction in disease activity in patients with relapsing MS

Abide Therapeutics initiates phase II study of ABX-1431 in Tourette syndrome

Patient recruitment ongoing in long-term phase III study of SK-1403

Mouse model mimics human tumors for testing MCL-1 inhibitors

First results presented for [177Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases

Lianyungang Ruzhong Pharmaceutical Co. and collaborators describe new IDO/TDO inhibitors

Heat shock protein 90 inhibitors discovered at Taipei Medical University

Evotec and Ferring enter strategic research alliance to treat fertility and gynecological conditions

Universite Paris Descartes and collaborators patent GRB14/insulin receptor interaction inhibitors

Eiger's phase II study of ubenimex in lower leg lymphedema does not meet endpoints

Shanghai Hengrui Pharmaceutical Co., Jiangsu Hengrui Medicine Co. discover TGFBR1 inhibitors

STING modulators identified at Boehringer Ingelheim

Phase II study of avexitide in post-bariatric hypoglycemia meets key endpoints

Zhejiang Hisun Pharmaceutical Co. patents acetyl-CoA carboxylase inhibitors

Phase III SUNRISE 2 trial of lemborexant in insomnia meets key endpoints

OCLI-070 inhibits osteoclast differentiation in ligature-induced experimental osteolysis

FDA approves Talzenna for germline BRCA-mutated HER2-negative breast cancer

Allergan plans ubrogepant NDA filing following successful outcome of safety studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...